Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy

Table 4 Clinicopathological profiles of the paired patients treated with NACT

Characteristic		Low difference value	High difference value	P
Characteristic		N = 41	N = 48	P
Age		54.73 ± 11.052	53.06 ± 11.434	0.636
< 40		3	9	0.115
> 40		38	39	0.115
No menopause		15	19	0.772
Menopause		26	29	0.772
T1		10	6	0.394
T2		22	30
T3		7	7
T4		2	5
N0		8	21	0.098
N1		9	8
N2		11	7
N3		13	12
Stage I		4	4	0.176
Stage II		11	22
Stage III		26	22
HR+		28	32	0.870
HR-		13	16	0.870
Her-2 positive		4	6	0.683
Her-2 negative		37	42	0.683
TNBC vs		9	10	0.898
No TNBC		32	38	0.898
Remission vs		22	45	< 0.001
No remission		19	3	< 0.001
recurrence		12	5	0.024
No recurrence		29	43	0.024
CR	TEC	14	17	0.495
	EC	8	14
	EC	5	7
	TX	14	10

Abbreviation: HR Hormone receptor, Her-2 Human epidermal growth factor receptor-2, TNBC Triple negative breast cancer, NACT Neoadjuvant chemotherapy, CR Chemical regime, TEC Docetaxel + anthracyclines + cyclophosphamide, EC Anthracyclines + cyclophosphamide, TC Docetaxel + cyclophosphamide, DP Docetaxel + platinum

ISSN: 1471-2407